SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

ACELYRIN, Inc. – ‘10-K’ for 12/31/23 – ‘EX-97.1’

On:  Thursday, 3/28/24, at 4:21pm ET   ·   For:  12/31/23   ·   Accession #:  1962918-24-32   ·   File #:  1-41696

5 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 3/28/24  ACELYRIN, Inc.                    10-K       12/31/23   94:11M

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.14M 
 2: EX-4.3      Instrument Defining the Rights of Security Holders  HTML     45K 
 3: EX-23.1     Consent of Expert or Counsel                        HTML     26K 
 7: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     41K 
                Awarded Compensation                                             
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     30K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     30K 
 6: EX-32       Certification -- §906 - SOA'02                      HTML     29K 
13: R1          Cover                                               HTML     92K 
14: R2          Audit Information                                   HTML     32K 
15: R3          Consolidated Balance Sheets                         HTML    123K 
16: R4          Consolidated Balance Sheets (Parenthetical)         HTML     62K 
17: R5          Consolidated Statements of Operations and           HTML     85K 
                Comprehensive Loss                                               
18: R6          Consolidated Statements of Redeemable Convertible   HTML    131K 
                Preferred Stock and Stockholders? Equity (Deficit)               
19: R7          Consolidated Statements of Redeemable Convertible   HTML     33K 
                Preferred Stock and Stockholders? Equity (Deficit)               
                (Parenthetical)                                                  
20: R8          Consolidated Statements of Cash Flows               HTML    131K 
21: R9          Consolidated Statements of Cash Flows               HTML     29K 
                (Parenthetical)                                                  
22: R10         Description of Business, Organization and           HTML     37K 
                Liquidity                                                        
23: R11         Summary of Significant Accounting Policies          HTML     69K 
24: R12         ValenzaBio Acquisition                              HTML     48K 
25: R13         Fair Value Measurements                             HTML     84K 
26: R14         Available-For-Sale Marketable Securities            HTML     59K 
27: R15         Consolidated Balance Sheet Components               HTML     66K 
28: R16         Significant Agreements                              HTML     44K 
29: R17         Commitments and Contingent Liabilities              HTML     50K 
30: R18         Redeemable Convertible Preferred Stock              HTML     50K 
31: R19         Derivative Tranche Liability                        HTML     30K 
32: R20         Common Stock                                        HTML     44K 
33: R21         Equity Incentive Plan                               HTML    109K 
34: R22         Related Party Transactions                          HTML     32K 
35: R23         Net Loss Per Share Attributable to Common           HTML     51K 
                Stockholders                                                     
36: R24         Income Taxes                                        HTML     80K 
37: R25         Subsequent Events                                   HTML     29K 
38: R26         Summary of Significant Accounting Policies          HTML    119K 
                (Policies)                                                       
39: R27         ValenzaBio Acquisition (Tables)                     HTML     38K 
40: R28         Fair Value Measurements (Tables)                    HTML     86K 
41: R29         Available-For-Sale Marketable Securities (Tables)   HTML     58K 
42: R30         Consolidated Balance Sheet Components (Tables)      HTML     70K 
43: R31         Commitments and Contingent Liabilities (Tables)     HTML     41K 
44: R32         Redeemable Convertible Preferred Stock (Tables)     HTML     40K 
45: R33         Common Stock (Tables)                               HTML     37K 
46: R34         Equity Incentive Plan (Tables)                      HTML     96K 
47: R35         Net Loss Per Share Attributable to Common           HTML     52K 
                Stockholders (Tables)                                            
48: R36         Income Taxes (Tables)                               HTML     88K 
49: R37         Description of Business, Organization and           HTML     88K 
                Liquidity (Details)                                              
50: R38         Summary of Significant Accounting Policies          HTML     48K 
                (Details)                                                        
51: R39         ValenzaBio Acquisition - Narrative (Details)        HTML    104K 
52: R40         ValenzaBio Acquisition - Schedule of Total          HTML     46K 
                Purchase Consideration (Details)                                 
53: R41         ValenzaBio Acquisition - Schedule of Allocation of  HTML     40K 
                Purchase Consideration (Details)                                 
54: R42         Fair Value Measurements - Schedule of Financial     HTML     78K 
                Instruments Measured on Recurring Basis (Details)                
55: R43         Fair Value Measurements - Schedule of Cash and      HTML     34K 
                Cash Equivalents and Marketable Securities                       
                (Details)                                                        
56: R44         Fair Value Measurements - Summary of Changes in     HTML     37K 
                Level 3 Liabilities (Details)                                    
57: R45         Fair Value Measurements - Narrative (Details)       HTML     47K 
58: R46         Fair Value Measurements - Summary of Significant    HTML     40K 
                Assumptions Used to Estimate Fair Value (Details)                
59: R47         Available-For-Sale Marketable Securities -          HTML     61K 
                Schedule of Available-for-Sale Marketable                        
                Securities (Details)                                             
60: R48         Available-For-Sale Marketable Securities -          HTML     39K 
                Narrative (Details)                                              
61: R49         Consolidated Balance Sheet Components - Schedule    HTML     41K 
                of Prepaid and Other Current Assets (Details)                    
62: R50         Consolidated Balance Sheet Components - Schedule    HTML     37K 
                of Prepaid and Other Noncurrent Assets (Details)                 
63: R51         Consolidated Balance Sheet Components - Property,   HTML     44K 
                Plant and Equipment (Details)                                    
64: R52         Consolidated Balance Sheet Components - Accrued     HTML     32K 
                Research and Development Expense (Details)                       
65: R53         Consolidated Balance Sheet Components - Schedule    HTML     37K 
                of Accrued Compensation and Other Current                        
                Liabilities (Details)                                            
66: R54         Significant Agreements (Details)                    HTML     73K 
67: R55         Commitments and Contingent Liabilities - Narrative  HTML     79K 
                (Details)                                                        
68: R56         Commitments and Contingent Liabilities - Schedule   HTML     37K 
                of Non-cancellable Purchase Obligations (Details)                
69: R57         Commitments and Contingent Liabilities - Summary    HTML     51K 
                of Maturity Analysis of Operating Lease Liability                
                (Details)                                                        
70: R58         Redeemable Convertible Preferred Stock - Narrative  HTML     62K 
                (Details)                                                        
71: R59         Redeemable Convertible Preferred Stock - Schedule   HTML     61K 
                of Convertible Preferred Stock (Details)                         
72: R60         Derivative Tranche Liability (Details)              HTML     49K 
73: R61         Common Stock - Narrative (Details)                  HTML     47K 
74: R62         Common Stock - Schedule of Common Stock Reserved    HTML     48K 
                for Future Issuance (Details)                                    
75: R63         Equity Incentive Plan - Narrative (Details)         HTML    242K 
76: R64         Equity Incentive Plan - Summary of Stock Option     HTML     82K 
                Activity (Details)                                               
77: R65         Equity Incentive Plan - Summary of Restricted       HTML     52K 
                Stock Unit Activity (Details)                                    
78: R66         Equity Incentive Plan - Summary of Performance      HTML     51K 
                Share Activity (Details)                                         
79: R67         Equity Incentive Plan - Schedule of Valuation       HTML     54K 
                Assumptions (Details)                                            
80: R68         Equity Incentive Plan - Schedule of Compensation    HTML     53K 
                Expense (Details)                                                
81: R69         Related Party Transactions (Details)                HTML     31K 
82: R70         Net Loss Per Share Attributable to Common           HTML     64K 
                Stockholders - Schedule of Basic and Diluted Net                 
                Loss Per Share (Details)                                         
83: R71         Net Loss Per Share Attributable to Common           HTML     45K 
                Stockholders - Schedule of Outstanding Shares Of                 
                Potentially Dilutive Securities (Details)                        
84: R72         Income Taxes - Narrative (Details)                  HTML     37K 
85: R73         Income Taxes - Schedule of Effective Income Tax     HTML     44K 
                Rate Reconciliation (Details)                                    
86: R74         Income Taxes - Schedule of Deferred Tax Assets      HTML     52K 
                (Details)                                                        
87: R75         Income Taxes - Summary of Operating Loss            HTML     34K 
                Carryforwards and Tax Credit Carryforwards                       
                (Details)                                                        
88: R76         Income Taxes - Summary of Uncertain Tax Positions   HTML     34K 
                (Details)                                                        
89: R77         Subsequent Events (Details)                         HTML     41K 
91: XML         IDEA XML File -- Filing Summary                      XML    171K 
94: XML         XBRL Instance -- slrn-20231231_htm                   XML   1.77M 
90: EXCEL       IDEA Workbook of Financial Report Info              XLSX    197K 
 9: EX-101.CAL  XBRL Calculations -- slrn-20231231_cal               XML    217K 
10: EX-101.DEF  XBRL Definitions -- slrn-20231231_def                XML    809K 
11: EX-101.LAB  XBRL Labels -- slrn-20231231_lab                     XML   1.80M 
12: EX-101.PRE  XBRL Presentations -- slrn-20231231_pre              XML   1.28M 
 8: EX-101.SCH  XBRL Schema -- slrn-20231231                         XSD    209K 
92: JSON        XBRL Instance as JSON Data -- MetaLinks              527±   822K 
93: ZIP         XBRL Zipped Folder -- 0001962918-24-000032-xbrl      Zip    665K 


‘EX-97.1’   —   Clawback Policy re: Recovery of Erroneously Awarded Compensation


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C: 
  a971incentivecompensatio  
ACELYRIN, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY 1. INTRODUCTION The Board of Directors (the “Board”) of ACELYRIN, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below. This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (“Rule 10D-1”) and Nasdaq Listing Rule 5608 (the “Listing Standards”). 2. EFFECTIVE DATE This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the “Effective Date”). Incentive Compensation is deemed “received” in the Company’s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period. 3. DEFINITIONS “Accounting Restatement” means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. “Accounting Restatement Date” means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement. “Administrator” means the Compensation Committee or, in the absence of such committee, the Board. “Code” means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder. “Compensation Committee” means the Compensation Committee of the Board. “Covered Officer” means each current and former Executive Officer. “Exchange” means the Nasdaq Stock Market. “Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended.


 
“Executive Officer” means the Company’s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. Executive officers of the Company’s parent(s) or subsidiaries are deemed executive officers of the Company if they perform such policy-making functions for the Company. Policy-making function is not intended to include policy-making functions that are not significant. Identification of an executive officer for purposes of this Policy would include at a minimum executive officers identified pursuant to Item 401(b) of Regulation S-K promulgated under the Exchange Act. “Financial Reporting Measures” means measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (“TSR”). A measure need not be presented in the Company’s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure. “Incentive Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure. “Lookback Period” means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date. “Recoverable Incentive Compensation” means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (i.e., on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards. “SEC” means the U.S. Securities and Exchange Commission. 4. RECOUPMENT (a) Applicability of Policy. This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Lookback Period. (b) Recoupment Generally. Pursuant to the provisions of this Policy, if there is an


 
Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company’s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed. (c) Impracticability of Recovery. Recoupment may be determined to be impracticable if, and only if: (i) the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to recover, and provide that documentation to the Exchange in accordance with the Listing Standards; or (ii) recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder. (d) Sources of Recoupment. To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii) cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, e.g., base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation. (e) No Indemnification of Covered Officers. Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company’s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy. (f) Indemnification of Administrator. Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the


 
Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy. (g) No “Good Reason” for Covered Officers. Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) “good reason” for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party. 5. ADMINISTRATION Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy. Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee’s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee). 6. SEVERABILITY If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable. 7. NO IMPAIRMENT OF OTHER REMEDIES Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer’s obligations to the Company, including, without limitation, termination of employment and/or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (“SOX 304”) that are applicable to the Company’s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and/or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and/or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law. 8. AMENDMENT; TERMINATION


 
The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard. 9. SUCCESSORS This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and/or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives. 10. REQUIRED FILINGS The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC. * * * * *


 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/28/248-K
For Period end:12/31/23
10/2/23
 List all Filings 


1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/28/24  ACELYRIN, Inc.                    S-8         3/28/24    4:133K


4 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/02/23  ACELYRIN, Inc.                    8-K:5,9     8/02/23   11:201K                                   Donnelley … Solutions/FA
 5/09/23  ACELYRIN, Inc.                    8-K:5,8,9   5/09/23    4:189K                                   Donnelley … Solutions/FA
 5/01/23  ACELYRIN, Inc.                    S-1/A                 20:9.1M                                   Donnelley … Solutions/FA
 4/13/23  ACELYRIN, Inc.                    S-1                   16:9.5M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001962918-24-000032   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., May 10, 8:07:52.1am ET